The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Generation IM’s Q2 2025 portfolio value declined to $15.73B, with 37 positions. Click here to read more about the portfolio's ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...